Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~1. informed consent~2. (BMI\>=30) or (BMI\>=27 with history of CV disease, hypertension, dyslipidemia, pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)~3. willing to comply with life-style intervention and treatment during the full duration of the study (approximately 54 weeks)~Exclusion Criteria:~* Hypersensitivity to any of the study medications~* Pregnancy or lactating women~* History of malignancies~* Use of pharmacologically active weight loss products~* Bariatric surgery~* Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening visit.~* HbA1c \>10% at the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LIK066 2.5mg qd (Epoch 3) (Type: EXPERIMENTAL): LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.
- Placebo (Epoch 3) (Type: PLACEBO_COMPARATOR): Matching placebo tablets for 24 weeks
- LIK066 10mg qd (Epoch 3) (Type: EXPERIMENTAL): LIK066 10mg qd (once daily) dosing frequency for 24 weeks
- LIK066 50mg qd (Epoch 3) (Type: EXPERIMENTAL): LIK066 50mg qd (once daily) dosing frequency for 24 weeks
- LIK066 150mg qd (Epoch 3) (Type: EXPERIMENTAL): LIK066 150mg qd (once daily) dosing frequency for 24 weeks
- LIK066 2.5mg bid (Epoch 3) (Type: EXPERIMENTAL): LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks
- LIK066 5mg bid (Epoch 3) (Type: EXPERIMENTAL): LIK066 5mg bid (once daily) dosing frequency for 24 weeks
- LIK066 25mg bid (Epoch 3) (Type: EXPERIMENTAL): LIK066 25mg bid (once daily) dosing frequency for 24 weeks
- LIK066 50mg bid (Epoch 3) (Type: EXPERIMENTAL): LIK066 50mg bid dosing frequency for 24 weeks
- LIK066 qd/LIK066 25mg qd (Epoch 4) (Type: EXPERIMENTAL): Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
- LIK066 bid/LIK066 35mg qd (Epoch 4) (Type: EXPERIMENTAL): Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
- Placebo/LIK066 25mg qd (Epoch 4) (Type: EXPERIMENTAL): Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
- Placebo/Placebo (Epoch 4) (Type: PLACEBO_COMPARATOR): Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete